The evidence for CI treatment is unusually strong for this field, and it points in one clear direction: office-based vision therapy with home reinforcement, not home exercises alone and not prism as a substitute.
What the CITT Actually Showed
The Convergence Insufficiency Treatment Trial, a large NIH-funded randomized study, compared office-based vision therapy against home-based exercises and against placebo therapy. Office-based therapy combined with home reinforcement produced symptom resolution or meaningful improvement in the large majority of children treated — a result that clearly outperformed home exercises alone. Just as important, those gains held up: roughly nine out of ten participants maintained their improvement at one-year follow-up, which is the kind of durability that separates a genuine treatment effect from a temporary adaptation.
What a Real Course of Treatment Looks Like
This isn't an open-ended commitment, but it's also rarely quick. A realistic course often runs anywhere from five months to a year, depending on severity and what else is present alongside the CI — and something else is almost always present. Convergence insufficiency essentially never shows up as a solo diagnosis; it exists alongside accommodative or oculomotor findings often enough that treating it as an isolated, standalone condition undersells how long real treatment usually takes. Weekly in-office sessions paired with daily home exercises between visits form the core structure regardless of timeline. The office sessions build skills under supervision and with equipment a home program can't replicate; the home exercises maintain and reinforce what's built in the office. Skipping the office component and relying on home exercises alone is one of the more common ways this gets under-treated, since the trial data specifically showed home exercises underperforming the combined approach.
Where Prism Fits, and Where It Doesn't
Prism prescribed in primary care rarely works for CI, and it's worth being direct about why: a general practice optometrist or ophthalmologist without behavioral or developmental training is typically leaning on Sheard's criterion to calculate a prescription, and Scheiman and Wick's own textbook on binocular vision management states plainly that base-in prism simply isn't a useful treatment for CI in the pre-presbyopic population. Prescribing it as a standalone fix in that population is treating a formula output as though it were a functional solution.
That doesn't mean prism has no place in CI care. Used actively within therapy, prism becomes a tool for sensitizing the brain to perceived spatial and optical change — a way of training the visual system's response to shifting demand, not a static correction meant to sit in a pair of glasses and quietly compensate for a deficit that never gets addressed.
Why Improvements Tend to Stick
Part of why CITT's results hold up at follow-up, rather than fading like some earlier approaches, is that properly structured vision therapy engages the fusional system directly and repeatedly under graded demand — closer to strength training than to a one-time fix. Newer research using fMRI has begun showing measurable changes in how the brain processes vergence demand after successful therapy, which is a fairly direct answer to the old assumption that these gains were purely behavioral compensation rather than genuine functional change.